Clinical trial sponsors and CROs are under unprecedented pressure to accelerate patient recruitment while upholding rigorous safety and compliance standards. Traditional site selection and enrollment processes often stretch over months, draining resources and delaying critical research. PolygrAI reimagines these early stages by converting feasibility assessments into dynamic, AI-driven interviews that pinpoint the most suitable trial sites in a fraction of the time. Investigators answer tailored questions about their patient demographics and site capabilities, allowing sponsors to compare and select locations with confidence. This rapid, data-informed approach not only shortens study startup timelines but also ensures that trials launch at sites best equipped to deliver robust results.

Once enrollment begins, the consent process becomes another source of friction and dropout risk. Static documents and one-size-fits-all explanations leave participants confused and disengaged. PolygrAI’s interactive consent interviews address this challenge by guiding each individual through protocol details at their own pace. The platform asks clarifying questions when participants struggle with complex concepts and records their understanding before capturing e-signatures. This personalized dialogue significantly enhances comprehension, fosters participant trust, and reduces the likelihood of early withdrawal, creating a solid foundation for long-term engagement.

As the study progresses, maintaining continuous safety oversight is paramount. Manual adverse-event reporting relies on participants recognizing and reporting symptoms, often days after they occur. PolygrAI embeds real-time safety screenings into every follow-up interaction, prompting deeper inquiry whenever a potential signal emerges. If a participant’s responses indicate new or worsening side effects, safety teams receive immediate alerts complete with AI-annotated transcripts and risk scores. This proactive monitoring transforms reactive data collection into a truly continuous vigil, allowing clinicians to intervene swiftly and protect patient well-being.

Compliance monitoring typically involves on-site visits and manual cross-checks of protocol adherence, which can be both costly and labor intensive. With PolygrAI, scheduled check-ins with site staff verify dosing schedules, visit compliance, and data quality automatically. Any deviation triggers a contextual follow-up interview that captures the necessary information for corrective action. Every conversation is encrypted, timestamped, and stored in an immutable audit trail that meets FDA, EMA, and ICH-GCP requirements. By centralizing interviews, analytics, and documentation, trial teams spend less time on paperwork and more time on strategic decision-making, keeping studies on schedule and under budget.